Wegovy: A Weight Loss Drug with Surprising Health Benefits

Novo Nordisk's weight-loss drug, Wegovy, has shown impressive revenue growth and has the potential to treat more than just weight loss. The drug may soon be approved for treating cardiovascular disease and has shown promise in improving fatty liver disease and curbing addictions. The anti-obesity drug market is growing rapidly, and Wegovy could generate significant sales for Novo Nordisk. The company's obesity-care segment has already seen substantial growth, with Wegovy's revenue rising by 481% this year. Novo Nordisk is investing in expanding its production capacity to address drug shortages. Despite its high valuation, Novo Nordisk's stock may still be a good investment considering Wegovy's potential and future growth prospects.